BAXTER INTERNATIONAL INC (BAX) Stock Price, Forecast & Analysis
USA - NYSE:BAX - US0718131099 - Common Stock
BAX Key Statistics, Chart & Performance
The current stock price of BAX is 18.47 USD. In the past month the price decreased by -20.01%. In the past year, price decreased by -42.21%.
BAX Latest News, Press Relases and Analysis
BAX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
Related stock screener links
About BAX
Company Profile
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Company Info
BAXTER INTERNATIONAL INC
One Baxter Parkway
Deerfield ILLINOIS 60015 US
CEO: Jose E. Almeida
Employees: 38000
Phone: 12249482000
BAXTER INTERNATIONAL INC / BAX FAQ
What does BAX do?
Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. The company is headquartered in Deerfield, Illinois and currently employs 38,000 full-time employees. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. The company provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
What is the stock price of BAXTER INTERNATIONAL INC today?
The current stock price of BAX is 18.47 USD. The price decreased by -1.23% in the last trading session.
Does BAX stock pay dividends?
BAXTER INTERNATIONAL INC (BAX) has a dividend yield of 0.21%. The yearly dividend amount is currently 1.16.
What is the ChartMill rating of BAXTER INTERNATIONAL INC stock?
BAX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about BAXTER INTERNATIONAL INC (BAX) stock?
25 analysts have analysed BAX and the average price target is 28.85 USD. This implies a price increase of 56.21% is expected in the next year compared to the current price of 18.47.
Is BAXTER INTERNATIONAL INC (BAX) expected to grow?
The Revenue of BAXTER INTERNATIONAL INC (BAX) is expected to grow by 5.45% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is BAXTER INTERNATIONAL INC worth?
BAXTER INTERNATIONAL INC (BAX) has a market capitalization of 9.49B USD. This makes BAX a Mid Cap stock.
BAX Technical Analysis
BAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BAX. Both the profitability and the financial health of BAX get a neutral evaluation. Nothing too spectacular is happening here.
BAX Financial Highlights
Over the last trailing twelve months BAX reported a non-GAAP Earnings per Share(EPS) of 2.41. The EPS decreased by -19.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.74% | ||
| ROE | -2.12% | ||
| Debt/Equity | 1.3 |
BAX Forecast & Estimates
25 analysts have analysed BAX and the average price target is 28.85 USD. This implies a price increase of 56.21% is expected in the next year compared to the current price of 18.47.
For the next year, analysts expect an EPS growth of -11.26% and a revenue growth 5.45% for BAX